Company intelligence

VERU

Veru Inc. · NASDAQ · Healthcare

Price$2.80+3.32% · +$0.09

Market cap44.94MEquity value

P / E-4.4Trailing ratio

Volume168.86KLatest session

Market data

VERU price chart

TradingView

Related signals

1 min delayed

Browse public VERU signals with their source context and measured market impact. Open any signal for its permanent analysis page.

VERUMay 28, 2025-16.92% since signal

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

VERU reports favorable Phase 2b trial results for enobosarm with semaglutide. No serious adverse events were observed, indicating strong safety profile for enobosarm. Enobosarm improves fat loss and retains lean mass in older patients significantly. Phase 3 program planned based on successful trial outcomes and results. VERU stock price surged 22.5% following promising safety and efficacy data.

View signal analysis

VERUJan 27, 2025-22.16% since signal

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

VERU stock drops 48.5% after Phase 2b study results. Enobosarm showed significant lean mass preservation compared to Wegovy alone. Patients using enobosarm lost 71% less lean mass than those on Wegovy. Major differences in fat loss favor enobosarm patients over placebo group. Safety data remains blind; full results expected by April 2025.

View signal analysis

Research